244:
and neuropharmacology of aminergic neurotransmitters in health and disease. In his M.Sc. and Ph.D. Studies he purified mitochondrial MAO and demonstrated two forms of the enzymes, which were later named A and B by
Johnson ( 1968). One of his most important contributions to science was working with Professor Merton Sandler in London University Post Graduate School to study MAO inhibitors as anti-depressants and anti-Parkinson drugs. While at Oxford University Medical School, a chance meeting with Professor Peter Riederer resulted in employing the MAO-B inhibitor, l-deprenyl (Later named selegiline) a failed anti depressant, in Parkinson's disease, since the human brain basal ganglia were rich in MAO-B and dopamine. The clinical study was a success and was confirmed by others in clinical studies and eventual approval of selegiline by FDA.
252:
in
Parkinson's and Alzheimer's diseases and ALS (amyotropic lateral sclerosis), where iron initiated oxidative stress may induce the process neurodegeneration. He was the first to demonstrate that iron chelators such as desferal and VK-28 were neuroprotective in animal models of Parkinson's disease since neurodegeneration of substantia nigra dopamine neuros results in accumulation of iron. Free iron may cause generation of free radicals and oxidative stress. His other pioneering contribution is the development of multi-target drugs for treatment of Parkinson's and Alzheimer's diseases possessing iron chleating, monomaine oxidase and cholinesterase inhibitory activities
477:, and Continental Pharmaceuticals, Brussels. He is president and CSO of Youdim Pharmaceutical. He is a discoverer of the anti-Parkinson drugs selelgiline (l-deprenyl) and developer of monoamine oxidase B inhibitor rasagiline (Azilect), which was considered to be the first disease modifying drug used for Parkinson's disease and TVP 3326, ladostigil, for Alzheimer's disease. Experts have recently questioned whether rasagiline actually has significant disease modifying properties.
25:
88:
243:
Youdim upon joining
Professor Theodore L Sourkes's laboratory at Allan Memorial Institute, McGill Department of Psychiatry, he began to work on the M.Sc. focusing on characteristics of the enzume monoamine oixdase (MAO), followed by Ph.D. He has focused most of his life on the field of neurochemistry
251:
He pioneered the study of brain iron dysregulation on brain function. This included its nutritional deficiency, which results in cognitive impairment and learning process in animal models and children with nutritional iron deficiency. And iron accumulation in brain neurons that degenerate resulting
234:
His father worked and traded with the
British and wanted that the boys to be educated in England. He and his brother were sent to England boarding school in UK. He had an ambition to go to medical school to study medicine and obtained his preclinical studies in Borough Polytechnique in London. he
247:
At
Technion in Haifa he discovered the second MAO B inhibitor, AGN1135, which was 20 times more potent than selegiline. Together with Prof. John Finberg and Teva Pharmecueitacl AGN1135 was developed as an anti Parkinson's Disease drug called rasagiline (Azilect), approved by FDA in 2006. This drug
348:
2000. Moussa B.H.Youdim 60th
Birthday, Festschrift Journal Neural Transmission dedicated to Moussa B.h. Youdim, 8th International Winter Conference on Neurodegenerative Diseases, (Tegernsee, Germany)
1063:
235:
was accepted at McGill
University in Montreal where he aobtained his B.Sc. degree. A lecture in neurochemsitry changed his mind about medical degree and decided to study brain chemistry.
207:(born, February 28, 1940) is an Israeli neuroscientist specializing in neurochemistry and neuropharmacology. He is the discoverer of both monoamine oxidase (MAO) B inhibitors l-deprenyl (
255:
Youdim has published almost nine hundred papers and reviews and edited 45 books in neurochemistry, neuropharmacology, multi-target drug development, and transcriptomics.
917:
414:
2009. Distinguished
Honorary Professor, Materica Medica of Chinese Academy of Sciences Shanghai University of Traditional Chinese Medicine, (Shanghai, China).
248:
had neuroprotective activity in cell culture and in vivo animal models of
Parkinson's disease and may have disease modifying activity in Parkinson's disease.
393:
2007. World
Federation of Neurology Award for Contribution to Parkinson’s Disease, 17th International Congress of Parkinson’s Disease, (Amsterdam, Holland).
519:
345:
1999. Moussa B..H.Youdim 60th Birthday, Festchrift, 15th Rappaport International Symposium, Molecular Biology of Neuropsychiatric Diseases, Haifa, Israel.
965:
873:
Naoi, M.; Maruyama, W.; Youdim, M.B.; Yu, P.; Boulton, A.A. (2003). "Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase".
1023:
1028:
524:
306:
1990. Upjohn Distinguished Lecture in Neuropharmacology of Parkinson’s Disease. Uniform Armed Forced University Medical School (Washington DC, USA).
411:
2009-2014. Distinguished Scientific Professor of Neurobiology, Yonsei World Central University Department of Neuroibology, (Seoul, South Korea).
387:
2007 Melvin Yahr Lecture, Can We Prevent Parkinson’s disease With Neurorestorative with drugs. Mount Sinai School of Medicine, (New York, USA).
216:
327:
1991-1998 Fogarty International Scholar In Residence at Fogarty Center For Advanced Study In Human Health NIH, NIDDK and NIMH (Bethesda, U
1002:
420:
2010 European College Neuropsychopharmacology(ECNP) Life Time Achievement Neuropsychopharmacology Prize, (Amsterdam, Netherland).
1033:
441:
2012. CINP (International College of Neuropsychopharmacology) Pioneering Neuropsychopharmacology Prize, (Stockholm, Sweden).
1038:
309:
1991. Claudius Galenus Gold Medal Prize for Parkinson Disease, l-Deprenyl (selegiline) Drug of the Year (Berlin, Germany).
807:
565:
384:
2007. Ron Arad Lecture, Multifunctional Drugs for Neurodegenerative Disorders, Royal Society of Medicine, (London, UK)
396:
2008. Thomas Schkeler Lecture, New Therapeutic Agents for Parkinson’s Disease. Ohio State University.(Columbus, Ohio)
63:
438:
2012. Giant Pioneer of Catecholamine Research Prize, 10th International Congress of Catecholamines, (Asilomar, USA).
342:
1999. “Shepard Foundation International Neurodegenerative Diseases Lecture”, University of Florida, Tallahassee, USA
270:
1974. Anna-Monika Prize in the field of neurobiology and the treatment of depressive disorders (Basel, Switzerland).
1068:
1058:
537:
456:
2024. The Tel Aviv University Aufzien Center and Israel Parkinson Association Parkinson Prize, (Tel Aviv, Israel).
1043:
754:"Neuroprotective Multifunctional Iron Chelators: From Redox-Sensitive Process to Novel Therapeutic Opportunities"
487:
297:
1990. Max Planck Distinguished Lecturer, Molecular Neuropharmacology of Parkinson’s Disease (Gottingen, Germany).
41:
499:
34:
336:
1997. “Honoree Causa” Honorary Doctor of Philosophy. Semmelweiss University Medical School (Budapest, Hungary)
1053:
390:
2007. Hirotaro Narabayashi Lecture. 17th International Congress of Parkinson’s Disease, (Amsterdam, Holland).
366:
2006. Herschel Rich Innovation Prize discovery of TVP-1022 a cardioprotective drug. Technion (Haifa, Israel).
402:
2008-2010 Distinguished Chair Professor, PolyTechnic University of Hong Kong University, (Hong Kong, China)
215:) as anti-Parkinson drugs which possess neuroprotective activities. He is currently professor emeritus at
357:
2002. Danish Neuroscience Presidential Lecture, Peter Henngaard Andersen Lecture (Copenhagen, Denmark).
360:
2002. Dutch Neuroscience Presidential Lecture, Hersenstichting Lecture and Prize (Amsterdam, Holland).
531:
493:
372:
2006. Journal of Neural Transmission, Suppl. Volume 71, dedicated to Moussa B.H. Youdim 65th birthday
294:
1989. Visiting Professor of Pharmacology, Uniformed Armed Forces Medical School (Washington DC, USA).
995:
947:
417:
2009. Distinguished Honorary Professor, Shanghai University Rejin Medical School, (Shanghai, China).
45:
830:
Youdim, M.B. (November 2003). "Rasagiline: an anti-Parkinson drug with neuroprotective activity".
752:
Weinreb, Orly; Amit, Tamar; Mandel, Silvia; Kupershmidt, Lana; Youdim, Moussa B.H. (2010-09-15).
435:
2012. Distinguished Honorary Professor, Doctor of Philosophy, Jinan University (GuanZhou, China).
231:
second of five children. The synagogue in the Jewish quarter of Tehran was owned by his family.
429:
2011. First Theodore L Sourkes Lecture, Parkinson Disease, McGill University (Montreal, Canada).
1048:
553:
505:
159:
The Tel Aviv University Aufzien Center and Israel Parkinson Association Parkinson Prize (2024)
1018:
996:
Prof. Emeritus Moussa Youdim is the recipient of the Israel Prize in Life Sciences for 2022
470:
285:
1984. Professor of Pharmacology Uniformed Armed Forces Medical School (Washington DC, USA).
599:"Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness"
282:
1980. Israel National Psychobiology Center Research Achievement Prize (Jerusalem, Israel).
8:
898:
855:
740:
691:
633:
598:
547:
405:
2008. Leir Visiting Professor Lecture, Mount Sinai School of Medicine, (New York, USA).
890:
847:
781:
773:
732:
724:
695:
683:
675:
638:
620:
579:
375:
2007. Neurochemical Research, Volume 32 dedicated to Moussa B.H. Youdim 65th birthday
859:
882:
839:
765:
744:
716:
667:
628:
610:
303:
1990. Senator Burda International Prize for Parkinson’s Disease (Vienna, Austria).
264:
1966-1971 Wellcome Trust Fellow, Postgraduate Medical School, University of London
902:
369:
2006. Henry Taub Prize for Excellence in Research, Technion, (Haifa, Israel)., Hi
40:
It may require cleanup to comply with Knowledge's content policies, particularly
977:
291:
1988. Maudsley Bequest Lecture, The Royal Society of Medicine (London, England).
886:
651:
559:
423:
2010 Elected Member of Leopoldina German Academy of Sciences (Halle, Germany).
1012:
843:
777:
728:
679:
624:
354:
2001. Polish Neuroscience-Pharmacology Presidential Lecture (Krakow, Poland).
918:"Panel: Teva's Azilect Data Close, but No Cigar for Parkinson's Delay Claim"
1003:
Prof. Emeritus Moussa Youdim Wins Prestigious Israel Prize in Life Sciences
894:
851:
785:
753:
736:
687:
642:
615:
432:
2011. Elected A Fellow of American College of Neuropsychopharmacology, USA.
408:
2009. Distinguished Honorary Professor, Qingdao University, Qingdao, China.
399:
2008. Distinguished Honorary Professor, University of Hong Hong, Hong Kong.
318:
1991. The B. Zondek Prize, Israel Endocrinology Society (Tel Aviv, Israel).
150:
769:
363:
2004. “Spring” Parkinson Lecture, Royal Society of Medicine (London, UK).
300:
1990. Sandoz Lecture, Pharmacology of Parkinson’s Disease (Tokyo, Japan).
101:
273:
1974. British Migraine Association Special Gold Medal (London, England).
594:
381:
2007. A. Zigler Lecture, Technion-Faculty of Medicine, (Haifa, Israel).
212:
208:
144:
703:
Youdim, Moussa B. H.; Edmondson, Dale; Tipton, Keith F. (April 2006).
378:
2006. Nathan Shock Lecture, NIH Institute of Ageing, (Baltimore, USA).
315:
1991. Eli Lilly Prize for Neuropsychopharmacology (Indianapolis, USA).
704:
655:
312:
1991. Deutscher Neuropharmakologie (AGNP) Prize (Nurenburg, Germany).
720:
671:
324:
1993. The New England Prize for Excellence In Science (Boston, USA).
474:
279:
1978. Wellcome Trust Fellow, McGill University (Montreal, Canada).
447:
2013. Elected Honorary Member of Israel Society for Neuroscience.
351:
2000. Hershel Rich Innovation Prize, Technion, (Haifa, Israel).
267:
1972. Wellcome Trust Fellow, College de France (Paris, France).
228:
133:
Development of anti-Parkinson drugs (selegiline and rasagiline)
110:
339:
1997. Henning Andersen International Prize (Stockholm, Sweden)
87:
466:
453:
2023. The Maimonides Award, Rambam Hospital, (Haifa, Israel).
450:
2022. The Israel Prize In life Sciences, (Jerusalem, Israel).
333:
1995. Hershel Rich Innovation Prize, Technion (Haifa, Israel)
808:"Curriculum Vitae and Publications Moussa B.H. Youdim Ph.D."
751:
321:
1992. The Israel Fertility Society Prize (Tel Aviv, Israel).
1064:
Academic staff of Technion – Israel Institute of Technology
705:"The therapeutic potential of monoamine oxidase inhibitors"
114:
105:
654:; Connor, James R.; Crichton, Robert R. (November 2004).
649:
426:
2011. EMET Prize for Brain Sciences, (Jerusalem, Israel).
288:
1986. Michael Landau Research Prize (Tel Aviv, Israel).
33:
A major contributor to this article appears to have a
702:
872:
656:"Iron, brain ageing and neurodegenerative disorders"
444:
2012. The Arvid Carlsson Medal, (Stockholm, Sweden).
485:On the editorial boards of 40 journals, including
276:1978. The Homayoon (Royal) Medal (Teheran, Iran).
1010:
520:International Journal of Neuropsychopharmacology
330:1994. Henning Anderson Prize (Stockholm, Sweden)
592:
823:
86:
1024:Israeli expatriates in the United Kingdom
632:
614:
219:and President of Youdim Pharmaceuticals.
188:Technion - Israel Institute of Technology
64:Learn how and when to remove this message
16:Israeli neuroscientist and pharmacologist
1029:Israeli expatriates in the United States
975:
866:
227:Youdim was born on February 28, 1940 in
460:
1011:
976:Leichman, Abigail Klein (2012-02-15).
829:
915:
650:Zecca, Luigi; Youdim, Moussa B. H.;
258:
238:
18:
480:
13:
832:Expert Review of Neurotherapeutics
758:Antioxidants & Redox Signaling
14:
1080:
940:
916:Young, Donna (18 October 2011).
538:European Journal of Pharmacology
44:. Please discuss further on the
23:
603:British Journal of Pharmacology
586:
488:British Journal of Pharmacology
465:Youdim served as consultant to
177:Neuroscience, Neuropharmacology
909:
800:
500:Journal of Neural Transmission
217:Technion - Faculty of Medicine
1:
1034:Israeli expatriates in Canada
793:
222:
1001:American Technion Society -
511:International Neurochemistry
7:
1039:Iranian emigrants to Israel
709:Nature Reviews Neuroscience
660:Nature Reviews Neuroscience
156:The Maimonides Award (2023)
10:
1085:
887:10.1163/156856003765764344
532:Frontiers in Pharmacology
494:Journal of Neurochemistry
198:
181:
173:
166:
147:for Brain Sciences (2011)
137:
129:
121:
97:
85:
78:
844:10.1586/14737175.3.6.737
526:Archives of Pharmacology
1069:Israel Prize recipients
1059:Israeli neuroscientists
153:in Life Sciences (2022)
1044:Scientists from Tehran
616:10.1038/sj.bjp.0706464
554:Neurochemical Research
506:Experimental Neurology
191:Youdim Pharmaceuticals
1005:Retrieved 2022-04-10.
998:Retrieved 2022-04-10.
978:"Parkinson's pioneer"
770:10.1089/ars.2009.2929
42:neutral point of view
1054:Israeli Mizrahi Jews
875:Inflammopharmacology
593:Youdim, Moussa B H;
471:TEVA Pharmaceuticals
461:Industry Involvement
205:Moussa B. H. Youdim
80:Moussa B. H. Youdim
548:Neuropsychobiology
515:Psychopharmacology
211:) and rasagiline (
92:Moussa B.H. Youdim
609:(S1): S287–S296.
580:Neurotherapeutics
259:Prizes and Awards
239:Scientific career
202:
201:
168:Scientific career
74:
73:
66:
37:with its subject.
1076:
991:
989:
988:
972:
970:
961:
959:
958:
934:
933:
931:
929:
913:
907:
906:
870:
864:
863:
827:
821:
820:
818:
817:
804:
789:
748:
699:
646:
636:
618:
481:Editorial Boards
90:
76:
75:
69:
62:
58:
55:
49:
35:close connection
27:
26:
19:
1084:
1083:
1079:
1078:
1077:
1075:
1074:
1073:
1009:
1008:
986:
984:
968:
964:
956:
954:
946:
943:
938:
937:
927:
925:
922:michaeljfox.org
914:
910:
871:
867:
828:
824:
815:
813:
806:
805:
801:
796:
721:10.1038/nrn1883
672:10.1038/nrn1537
666:(11): 863–873.
652:Riederer, Peter
589:
566:CNS Drug Review
543:Biogenic Amines
483:
463:
261:
241:
225:
194:
162:
117:
108:
93:
81:
70:
59:
53:
50:
39:
28:
24:
17:
12:
11:
5:
1082:
1072:
1071:
1066:
1061:
1056:
1051:
1046:
1041:
1036:
1031:
1026:
1021:
1007:
1006:
999:
992:
973:
962:
952:www.avphar.com
942:
941:External links
939:
936:
935:
924:. FoxFeed Blog
908:
865:
822:
798:
797:
795:
792:
791:
790:
764:(6): 919–949.
749:
715:(4): 295–309.
700:
647:
588:
585:
575:Drugs of Today
560:Brain Research
482:
479:
462:
459:
458:
457:
454:
451:
448:
445:
442:
439:
436:
433:
430:
427:
424:
421:
418:
415:
412:
409:
406:
403:
400:
397:
394:
391:
388:
385:
382:
379:
376:
373:
370:
367:
364:
361:
358:
355:
352:
349:
346:
343:
340:
337:
334:
331:
328:
325:
322:
319:
316:
313:
310:
307:
304:
301:
298:
295:
292:
289:
286:
283:
280:
277:
274:
271:
268:
265:
260:
257:
240:
237:
224:
221:
200:
199:
196:
195:
193:
192:
189:
185:
183:
179:
178:
175:
171:
170:
164:
163:
161:
160:
157:
154:
148:
141:
139:
135:
134:
131:
130:Known for
127:
126:
123:
119:
118:
109:
99:
95:
94:
91:
83:
82:
79:
72:
71:
31:
29:
22:
15:
9:
6:
4:
3:
2:
1081:
1070:
1067:
1065:
1062:
1060:
1057:
1055:
1052:
1050:
1049:Living people
1047:
1045:
1042:
1040:
1037:
1035:
1032:
1030:
1027:
1025:
1022:
1020:
1017:
1016:
1014:
1004:
1000:
997:
993:
983:
979:
974:
967:
963:
953:
949:
945:
944:
923:
919:
912:
904:
900:
896:
892:
888:
884:
881:(2): 175–81.
880:
876:
869:
861:
857:
853:
849:
845:
841:
838:(6): 737–49.
837:
833:
826:
812:
811:docplayer.net
809:
803:
799:
787:
783:
779:
775:
771:
767:
763:
759:
755:
750:
746:
742:
738:
734:
730:
726:
722:
718:
714:
710:
706:
701:
697:
693:
689:
685:
681:
677:
673:
669:
665:
661:
657:
653:
648:
644:
640:
635:
630:
626:
622:
617:
612:
608:
604:
600:
596:
591:
590:
584:
582:
581:
576:
572:
568:
567:
562:
561:
556:
555:
550:
549:
544:
540:
539:
534:
533:
528:
527:
522:
521:
516:
512:
508:
507:
502:
501:
496:
495:
490:
489:
478:
476:
472:
468:
455:
452:
449:
446:
443:
440:
437:
434:
431:
428:
425:
422:
419:
416:
413:
410:
407:
404:
401:
398:
395:
392:
389:
386:
383:
380:
377:
374:
371:
368:
365:
362:
359:
356:
353:
350:
347:
344:
341:
338:
335:
332:
329:
326:
323:
320:
317:
314:
311:
308:
305:
302:
299:
296:
293:
290:
287:
284:
281:
278:
275:
272:
269:
266:
263:
262:
256:
253:
249:
245:
236:
232:
230:
220:
218:
214:
210:
206:
197:
190:
187:
186:
184:
180:
176:
172:
169:
165:
158:
155:
152:
149:
146:
143:
142:
140:
136:
132:
128:
124:
120:
116:
112:
107:
103:
100:
96:
89:
84:
77:
68:
65:
57:
47:
43:
38:
36:
30:
21:
20:
985:. Retrieved
981:
955:. Retrieved
951:
926:. Retrieved
921:
911:
878:
874:
868:
835:
831:
825:
814:. Retrieved
810:
802:
761:
757:
712:
708:
663:
659:
606:
602:
587:Publications
578:
574:
571:Future Drugs
570:
564:
558:
552:
546:
542:
536:
530:
525:
518:
514:
510:
504:
498:
492:
486:
484:
464:
254:
250:
246:
242:
233:
229:Tehran, Iran
226:
204:
203:
182:Institutions
167:
151:Israel Prize
60:
51:
32:
1019:1940 births
994:Technion -
966:"Kenes Bio"
928:21 February
595:Bakhle, Y S
122:Nationality
102:February 28
1013:Categories
987:2021-11-02
957:2021-11-02
816:2024-04-01
794:References
475:Ciba Geigy
223:Early life
209:Selegiline
145:EMET Prize
54:April 2018
982:ISRAEL21c
778:1523-0864
729:1471-003X
696:205500060
680:1471-003X
625:0007-1188
46:talk page
895:15035819
860:23857497
852:19810877
786:20095867
737:16552415
688:15496864
643:16402116
597:(2006).
745:1207867
634:1760741
213:Azilect
125:Israeli
901:
893:
858:
850:
784:
776:
743:
735:
727:
694:
686:
678:
641:
631:
623:
577:, and
174:Fields
138:Awards
111:Tehran
969:(PDF)
948:"Bio"
903:60465
899:S2CID
856:S2CID
741:S2CID
692:S2CID
473:Ltd;
467:Roche
930:2016
891:PMID
848:PMID
782:PMID
774:ISSN
733:PMID
725:ISSN
684:PMID
676:ISSN
639:PMID
621:ISSN
115:Iran
106:1940
98:Born
883:doi
840:doi
766:doi
717:doi
668:doi
629:PMC
611:doi
607:147
1015::
980:.
950:.
920:.
897:.
889:.
879:11
877:.
854:.
846:.
834:.
780:.
772:.
762:13
760:.
756:.
739:.
731:.
723:.
711:.
707:.
690:.
682:.
674:.
662:.
658:.
637:.
627:.
619:.
605:.
601:.
583:.
573:,
569:,
563:,
557:;
551:,
545:,
541:,
535:,
529:,
523:,
517:.
513:,
509:,
503:,
497:,
491:,
469:,
113:,
104:,
990:.
971:.
960:.
932:.
905:.
885::
862:.
842::
836:3
819:.
788:.
768::
747:.
719::
713:7
698:.
670::
664:5
645:.
613::
67:)
61:(
56:)
52:(
48:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
